Asset Details
Do you wish to reserve the book?
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
Do you wish to request the book?
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
2021
Overview
Preclinical studies have suggested that epigenetic therapy could enhance immunogenicity of cancer cells. We report the results of the PEMDAC phase 2 clinical trial (
n
= 29; NCT02697630) where the HDAC inhibitor entinostat was combined with the PD-1 inhibitor pembrolizumab in patients with metastatic uveal melanoma (UM). The primary endpoint was objective response rate (ORR), and was met with an ORR of 14%. The clinical benefit rate at 18 weeks was 28%, median progression free survival was 2.1 months and the median overall survival was 13.4 months. Toxicities were manageable, and there were no treatment-related deaths. Objective responses and/or prolonged survival were seen in patients with
BAP1
wildtype tumors, and in one patient with an iris melanoma that exhibited a UV signature. Longer survival also correlated with low baseline ctDNA levels or LDH. In conclusion, HDAC inhibition and anti-PD1 immunotherapy results in durable responses in a subset of patients with metastatic UM.
Trial registration
ClinicalTrials.gov registration number: NCT02697630 (registered 3 March 2016). EudraCT registration number: 2016–002114-50.
The authors report the results of the phase II PEMDAC clinical study testing the combination of the HDAC inhibitor entinostat with the anti- PD-1 antibody pembrolizumab in uveal melanoma. Low tumor burden, a wildtype BAP1 gene in the tumor or iris melanoma correlates with response and longer survival.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 38/39
/ 38/91
/ 692/4017
/ 96/31
/ Antibodies, Monoclonal, Humanized - administration & dosage
/ bap1
/ Benzamides - administration & dosage
/ cells
/ DNA
/ Humanities and Social Sciences
/ Humans
/ ii trial
/ Melanoma
/ Patients
/ pd-1
/ Pyridines - administration & dosage
/ Science
/ Science & Technology - Other Topics
/ Survival
/ Tumor Suppressor Proteins - genetics
/ Tumors
/ Ubiquitin Thiolesterase - genetics
